Journal article icon

Journal article

Phase I trial of the single-chain urokinase intrapleural LTI-01 in complicated parapneumonic effusions or empyema

Abstract:

BACKGROUND:Current dosing of intrapleural fibrinolytic therapy (IPFT) in adults with complicated parapneumonic effusion (CPE) / empyema is empiric, as dose-escalation trials have not previously been conducted. We hypothesized that LTI-01 (scuPA), which is relatively resistant to PA inhibitor-1 (PAI-1), would be well-tolerated. METHODS:This was an open-label, dose-escalation trial of LTI-01 IPFT at 50,000-800,000 IU daily for up to 3 days in adults with loculated CPE/empyema and failed pleural...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1172/jci.insight.127470

Authors


Expand authors...
Publisher:
American Society for Clinical Investigation Publisher's website
Journal:
JCI Insight Journal website
Volume:
4
Issue:
10
Article number:
e127470
Publication date:
2019-04-18
Acceptance date:
2019-04-12
DOI:
EISSN:
2379-3708
Pmid:
30998508
Source identifiers:
1003134
Language:
English
Keywords:
Pubs id:
pubs:1003134
UUID:
uuid:6c59bed8-37fb-4c55-8651-d4b5ef3d58d0
Local pid:
pubs:1003134
Deposit date:
2019-06-05

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP